Pharma producers to pay a differentiated clawback tax for new subsidized medicine

Pharmaceutical companies are set to pay a differentiated clawback tax, based on cost-volume contracts, for the new medicine that will go, under certain conditions, on the list of reimbursed drugs. For the rest of the products on the list, the contribution will remain unchanged, Mediafax reports.
The new norms are stipulated through an emergency ordinance that is bringing changed to the government ordinance OUG 77/2011concerning the establishment of a contribution to finance certain health expenses.
“Cost-volume or cost-volume-result contracts can be closed within the limit of the funds obtained from excluding and/or the change in the reimbursement percentage of some drugs included on the list, as well as from applying certain pharma-related policies. If the cost-volume or cost-volume-result contracts are not closed, the drugs will not be included on the approved list,” shows the document.
The contribution will be paid quarterly and it will be calculated by applying the percentage stipulated in the cost-volume/ cost-volume-result contacts to the value of the quarterly consumption.
The value of the quarterly consumption is computed by applying the percentage negotiated on the retail price without VAT/distribution price without VAT, with reference to the consumption of drugs each quarter in comparison to volumes included in cost-volume agreements.
Authorities claim that cost-volume contracts and cost-volume-result contracts increase the population access to therapies. According to Health Minister Nicolae Banicioiu 40 new molecules and new combinations of substances have been introduced so far and the updating process in ongoing.